June 2024 Newsletter

Welcome to the monthly Crown Bioscience newsletter. Discover some of our monthly highlights to keep up to date with recent developments and to learn more about our services. Don't forget to follow us on LinkedIn to avoid missing our daily updates!

Last month, we announced our pivotal role in several scientific innovation projects funded by European grants. These projects aim to advance cancer treatments and the development of the tools to do so, employing cutting-edge techniques such as organoid and ex vivo patient tissue technologies, with the goal of bridging the gap between research and patient care.

With active participation in these high-impact projects, we continue our unwavering dedication to scientific excellence, and the mission to help customers develop novel therapies aims to ensure that patients receive the right treatment at the right time.

Imaging technologies enhance the value of orthotopic and systemic in vivo models by providing real-time and spatial tracking of disease progression. In this webinar, Dr. Bryan Miller will cover the latest advancements in imaging technologies for preclinical in vivo oncology models and discuss how to maximize your studies with the most suitable imaging modalities.

Our latest blog post reveals how our groundbreaking platform OrganoidXplore enables rapid, large-scale testing of compounds on diverse organoid panels. Unlock biologically relevant data to enhance your research in just weeks. 

Comprehensively profile genes associated with tumor immunity with our Mouse I/O RNA-Seq Panel. Discover our NGS-based assay for detecting mRNA expression of 1080 TME-related genes. Download the gene list now.

Empower your immuno-oncology research with banked and prospective biospecimens from treated patients, plus outstanding lab services for multiplex fluorescent IHC, proteomics, genomics, and cell biology.

MuScreen provides a cost-effective screening platform, with a free vehicle arm and shared cost of the positive control arm. Register before July 12th to fast-track your in vivo preclinical immunotherapy development.

The US Food and Drug Administration’s (FDA) approved 55 new drugs in 2023. This blog post shares those successes within oncology drug development in 2023, the trends and setbacks, and the outlook for 2024.

We recently completed a global collaboration agreement with the Shanghai Model Organisms Center (SMOC). This collaboration will help bridge the gap between scientific discovery and clinical application.

© 2024 Crown Bioscience

Crown Bioscience, Inc. 16550 West Bernardo Drive, Building 5, Suite 525, San Diego, CA 92127, United States